Which country is larotrectinib produced in?

Larotrectinib was originally developed by the American company Loxo Oncology for the treatment of NTRK gene fusion-positive solid tumors. As a breakthrough precision-targeted drug, its remarkable efficacy has quickly attracted attention. In 2019, Loxo Oncology was acquired by the American pharmaceutical giant Eli Lilly (Eli Lilly). Therefore, the production and global sales of larotrectinib are currently handled by Eli Lilly.

The production of larotrectinib’s original drug is mainly concentrated in the United States, and is produced by Eli Lilly and Company in strict accordance with international drug production standards (GMP) to ensure the quality and efficacy of the drug. In addition, Eli Lilly is also responsible for the supply of larotrectinib in Europe and other regions, so the German version, European version and other original drugs are also distributed by Eli Lilly. At the same time, the original drugs sold in the Hong Kong market are also provided by Eli Lilly and Company. These versions are internationally recognized as high-quality drugs.

In addition to the original drug, larotrectinib also has generic versions, mainly produced by pharmaceutical companies in Laos and Bangladesh. These generic drugs are supported by local regulations and have lower production costs, making them more affordable. The price of larotinib in Laos and Bangladesh is only about 20%-30% of that of the original drug, but there may be certain differences from the original drug in terms of production technology and supervision.

To sum up, the original drug of larotrectinib is produced by Eli Lilly and Company of the United States and distributed to multiple markets including Europe and Hong Kong, China; the generic drug is produced by pharmaceutical companies in Laos and Bangladesh. When choosing drugs, patients must purchase them through formal channels and use them strictly in accordance with the doctor's instructions to ensure treatment effectiveness and safety.